Review
Immunology
Zi-yun Qiao, Zi-jie Zhang, Zi-cheng Lv, Huan Tong, Zhi-feng Xi, Hao-xiang Wu, Xiao-song Chen, Lei Xia, Hao Feng, Jian-jun Zhang, Qiang Xia
Summary: The study investigated the safety and efficacy of neoadjuvant PD-1 blockade in LT recipients with HCC, showing promising results in terms of objective response rate and disease control rate. The combination therapy of PD-1 blockade and tyrosine kinase inhibitors demonstrated effective outcomes with acceptable mortality, highlighting the potential of this approach in transplant recipients.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Saad Alghamdi, Waleed Al-Hamoudi
Summary: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. With the development of immunotherapy, immune checkpoint inhibitors (ICIs) have emerged as a safe and beneficial option for HCC treatment. However, there are concerns about adverse effects, such as graft rejection and graft loss. This review discusses the potential of immunotherapy as an adjunct to liver transplantation in both pre- and post-transplantation settings. It emphasizes the need for larger, well-designed clinical trials to identify patients who will benefit most from ICI treatment in the transplant setting and to optimize the use of this adjunct treatment.
Review
Immunology
Qian Li, Jingjing Han, Yonglin Yang, Yu Chen
Summary: Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide. In recent years, immunotherapy using immune checkpoint inhibitors, particularly targeting the PD-1/PD-L1 axis, has brought fundamental changes to the treatment of advanced HCC. However, challenges remain and combination therapy may be a better option to improve the low remission rate.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Pharmacology & Pharmacy
Jinhua Liu, Zichao Chen, Yaqun Li, Wenjie Zhao, JiBiao Wu, Zhen Zhang
Summary: Programmed death protein 1 (PD1) is an important immune checkpoint on T cells that plays a crucial role in downregulating the immune system and promoting self-tolerance, while its ligand, programmed cell death ligand 1 (PDL1), is overexpressed in malignant tumor cells, contributing to immune evasion and treatment failure. Despite the clinical efficacy of PD1/PDL1 inhibitors in many tumors, some patients may develop drug resistance, highlighting the need for further research into improving targeted therapies and understanding the associated safety issues.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Cell Biology
Shane Handelsman, Juliana Overbey, Kevin Chen, Justin Lee, Delour Haj, Yong Li
Summary: Over the past decade, PD-L1 has become a prominent target in cancer immunotherapies, but its potential as an immunosuppressive therapy has been limited. This review presents the immunological basis of graft rejection and GVHD, and summarizes the molecular interactions of PD-L1 and PD-1. It also provides a translational perspective on how manipulating PD-L1 can increase immune tolerance and improve graft survival.
Review
Immunology
Qingyi Wang, Bin Xie, Shuang Liu, Ying Shi, Yongguang Tao, Desheng Xiao, Wenxiang Wang
Summary: The fruitful results of tumor immunotherapy have established its indispensable status in regulating the tumorous immune context. The treatment of programmed cell death receptor 1 (PD-1) blockade is considered one of the most promising approaches for cancer control, with significant efficacy shown in various cancer types. However, more research is needed to understand how anti-PD-1 therapy impacts the immune microenvironment and why some patients develop resistance to PD-1 blockade.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Chemistry, Medicinal
Xuchao Yang, Binbin Cheng, Yao Xiao, Mingming Xue, Ting Liu, Hao Cao, Jianjun Chen
Summary: Novel CA-4 analogs were designed, synthesized, and bio-evaluated as dual inhibitors of tubulin polymerization and PD-1/PD-L1, among which TP5 showed strong inhibitory effects against cancer cell lines and moderate anti-PD-1/PD-L1 activity. In vivo efficacy studies demonstrated that TP5 could significantly suppress tumor growth without causing significant toxicity, suggesting its potential as a starting point for developing more potent dual inhibitors.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Pharmacology & Pharmacy
Chengliang Sun, Yao Cheng, Xiaojia Liu, Gefei Wang, Wenjian Min, Xiao Wang, Kai Yuan, Yi Hou, Jiaxing Li, Haolin Zhang, Haojie Dong, Liping Wang, Chenguang Lou, Yanze Sun, Xinmiao Yu, Hongbin Deng, Yibei Xiao, Peng Yang
Summary: Programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) have emerged as promising immune checkpoint targets for cancer immunotherapy. This study focuses on the development of small-molecule inhibitors with improved binding capacity to PD-L1 protein. A novel phthalimide derivative, P39, was identified as the best inhibitor, which not only inhibited PD-1/PD-L1 interaction but also enhanced the killing efficacy of immune cells on cancer cells. P39 exhibited favorable safety profiles and showed significant in vivo antitumor activity through promoting CD8+ T cell activation.
ACTA PHARMACEUTICA SINICA B
(2022)
Article
Biochemistry & Molecular Biology
Fengling Wang, Wenling Ye, Yongxing He, Haiyang Zhong, Yongchang Zhu, Jianting Han, Xiaoqing Gong, Yanan Tian, Yuwei Wang, Shuang Wang, Shaoping Ji, Huanxiang Liu, Xiaojun Yao
Summary: Targeting the PD-1/PD-L1 immunologic checkpoint has provided a breakthrough in cancer therapy. A small molecule inhibitor called CBPA was identified as an effective PD-L1 inhibitor with blocking activity and T-cell reinvigoration capacity. CBPA also showed significant antitumor efficacy in mouse tumor models without observable organ toxicity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Nutrition & Dietetics
Yuqian Wang, Lingeng Lu, Changquan Ling, Ping Zhang, Rui Han
Summary: This study proposes a novel therapeutic strategy for breast cancer treatment by combining a diet containing HDAC2 inhibitors with PD-1/PD-L1 inhibitors, offering promising possibilities for improving treatment outcomes.
Review
Oncology
Shihao Li, Yi Zhu, Zhijian Xu, Jianjun Liu, Hongwei Liu
Summary: The discovery of immune checkpoint inhibitors (ICIs) has made significant progress in fighting against malignant tumors. This case suggests that a PD-1 inhibitor (tislelizumab) alone may be an effective treatment strategy for solitary renal calyceal urothelial carcinoma.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biotechnology & Applied Microbiology
Tianrui Yang, Ziren Kong, Wenbin Ma
Summary: Immune checkpoint inhibitors have revolutionized tumor immunotherapy, but face challenges in the treatment of glioblastoma due to its unique immunosuppressive characteristics. Recent clinical studies are focusing on combination therapies involving standard treatments, targeted therapies, and other immunotherapies to improve outcomes for patients with GBM.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Oncology
Ashray Maniar, Alyson Haslam, Vinay Prasad
Summary: Many control-arm patients in first-line trials did not receive PDI with established efficacy, highlighting the need for standardized approach to disease progression for these patients.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Gastroenterology & Hepatology
Zhengqing Lei, Weihu Ma, Anfeng Si, Yuhua Zhang, Facai Yang, Qiushi Yu, Haolan Tang, Qianru Xiao, Jiahua Zhou, Kui Wang, Yufu Tang, Tao Han, Guowen Yin, Jinhong Chen, Xiufeng Liu, Hua Zhao, Decai Yu, Tao Luo, Qing Wang, Maolin Yan, Xianhai Mao, Jing Li, Kai Wang, Jingdong Li, Yongyi Zeng, Dequan Ding, Tingsong Chen, Xiaofeng Wu, Yongxiang Xia, Kang Wang, Weixing Guo, Guangyu Zhu, Shan Gao, Norbert Hueser, Wan Y. Lau, Tianqiang Song, Shuqun Cheng, Feng Shen, Zhangjun Cheng
Summary: This study compared the efficacy of different anti-PD-1 combination therapies as the first-line treatment for uICC. The results showed that ICI-chemo and ICI-target therapies had better survival outcomes and fewer adverse events compared to chemotherapy. ICI-target-chemo had similar efficacy to ICI-chemo but resulted in more adverse events.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Medicine, General & Internal
Syed Munib, Tanveer Ahmed, Raheel Ahmed, Najam-ud-Din
Summary: The study aimed to determine the histopathological pattern in living-related kidney transplant recipients from a transplant center in Khyber Pakhtunkhwa, Pakistan. Mixed lesions were the predominant findings, followed by others (mostly CNI toxicity) and IFTA categories. The frequency of acute/active rejections was low, while chronic changes were higher, in line with delayed biopsies.
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN
(2021)
Letter
Oncology
Chung-Kuan Wu, Shang-Jyh Kao, Hung-Chih Lai
JOURNAL OF THORACIC ONCOLOGY
(2018)
Article
Medicine, General & Internal
Chung-Kuan Wu, Chia-Hsun Lin, Chih-Cheng Hsu, Der-Cherng Tarng, Chew-Teng Kor, Yi-Chun Chen, Chia-Lin Wu, Chia-Chu Chang
Article
Chemistry, Multidisciplinary
Jia-An Chou, Chieh-Lin Chung, Po-Cheng Ho, Chun-Hao Luo, Yu-Han Tsai, Chung-Kuan Wu, Chiung-Wen Kuo, Yu-Sheng Hsiao, Hsiao-hua Yu, Peilin Chen
FRONTIERS IN CHEMISTRY
(2019)
Review
Cardiac & Cardiovascular Systems
Tien-Yu Wu, Chung-Kuan Wu, Yen-Yang Chen, Chia-Hsun Lin
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
(2020)
Article
Surgery
Yen-Yang Chen, Chung-Kuan Wu, Chia-Hsun Lin
JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC DISORDERS
(2020)
Article
Medicine, General & Internal
Chung-Kuan Wu, Chia-Lin Wu, Tzu-Cheng Su, Yu Ru Kou, Chew-Teng Kor, Tzong-Shyuan Lee, Der-Cherng Tarng
JOURNAL OF CLINICAL MEDICINE
(2019)
Article
Medicine, General & Internal
Shu-Fen Niu, Chung-Kuan Wu, Nai-Chen Chuang, Ya-Bei Yang, Tzu-Hao Chang
Summary: The Early CKD Care Programme was found to be an independent protective factor against progression of early CKD in patients with stage I-IIIa. The programme participants showed lower risk of progression to stage IIIb compared to non-participants, even with higher comorbidities. Furthermore, the programme was especially beneficial for patients with CKD stage IIIa in preventing progression to stage IIIb.
Article
Biochemistry & Molecular Biology
Chung-Kuan Wu, Chia-Lin Wu, Tzong-Shyuan Lee, Yu Ru Kou, Der-Cherng Tarng
Summary: The study found that TRPA1 plays a role in AKI by sensing oxidative stress and regulating inflammation in renal tubular cells. TRPA1 expression increased in patients with AKI and in a mouse model of IR-induced injury, highlighting its importance in kidney injury. In vitro experiments showed that TRPA1 activation by ROS under hypoxia-reoxygenation injury conditions led to increased intracellular Ca2+ level and activation of inflammatory signaling pathways.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Chung-Kuan Wu, Ji-Fan Lin, Tzong-Shyuan Lee, Yu Ru Kou, Der-Cherng Tarng
Summary: TRPA1 plays dual roles in sensory neurons and non-neuronal cells, promoting tissue repair, clearing harmful stimuli, and inducing protective responses, while also potentially contributing to disease progression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Dermatology
Wan-Ting J. Lee, Chien-Chang Lee, Chung-Kuan Wu, Ching-Hwa Lin, Te-Yu Lo, Chieh-Chen Huang, Sam L. Kahler, Haw-Yueh Thong
Summary: This study provides preliminary epidemiologic data on the prevalence of dermatologic disease in the adult population of Palau. It highlights the heavy burden of dermatologic disease in Palau compared to other Oceanic nations, emphasizing the need for ongoing dermatology services to achieve health equality.
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2022)
Article
Medicine, General & Internal
Chung-Kuan Wu, Der-Cherng Tarng, Chih-Yu Yang, Jyh-Gang Leu, Chia-Hsun Lin
Summary: The study found that AVG access type, acute myocardial infarction, and high ferritin levels are risk factors for re-intervention post-PTA. These findings may be useful in the development of prophylactic strategies for monitoring VA function and tailoring surveillance programs for these dialysis patients.
Article
Rehabilitation
Lin-Fen Hsieh, Ying-Chen Kuo, Yu-Hao Huang, Ya-Fang Liu, Tien-Lee Hsieh
Summary: This study aimed to investigate whether the combination of corticosteroid subdeltoid injections and physiotherapy was more effective than either treatment alone in patients with chronic subacromial bursitis. The results showed that both corticosteroid injection and combined treatment were superior to physiotherapy alone in terms of shoulder flexion and treatment effect. However, the physiotherapy group had the lowest recurrence rate.
CLINICAL REHABILITATION
(2023)
Article
Dermatology
Haw-Yueh Thong, Chung-Kuan Wu, Ching-Hwa Lin, Te-Yu Lo, Chieh-Chen Huang
DERMATOLOGICA SINICA
(2020)